Imitrex Uses, Dosage, Side Effects & Warnings - Sumatriptan belongs to a class of medications known as 5-hydroxytryptamine agonists (also ed "triptans"). Sumatriptan can pass into breast milk and may harm a nursing baby. Do not breast-feed within 12 hours after using Imitrex.
Imitrex Keep a Clear Head It is used to treat mraine headaches with or without aura (warning sns that occur prior to the onset of a mraine). Under the influence of Imitrex, throbbing or pulsating pain, nausea, and. It is not allowed to take Imitrex by pregnant and breast feeding women it is likely to.
IMITREX ) while breastfeeding.” The answer to that last question is almost always yes. Nursing Mothers Sumatriptan is excreted in human breast milk. Therefore, caution should be exercised when considering the administration of IMITREX Tablets to a nursing woman.
Imitrex - Uses, Side Effects, Interactions - Imitrex is a medication applied in treatment of mraine headaches. Imitrex. sumatriptan. DIN Drug Identification Number. 02230420 IMITREX 20MG. If you are a breast-feeding mother and are taking sumatriptan, it may affect.
Is It Safe To Have Imitrex Sumatriptan While The pain of mraine headaches is thought to be caused by dilated blood vessels inside the head. Studies reveal that one 6 mg administration of an Imitrex dose results in a transfer of about 0.24 % of the dose into the breast milk, and in turn to your infant.
Sumatriptan Oral Tablet Side Effects, Dosage, Uses & More Agitation Cardiac arrhythmia: V-fib/V-tach (rare) Dysuria Eye irritation Flushing MI and coronary artery vasospasm in patients with CAD risk factors (extremely rare) Nasal discomfort Palpitations Tingling Weakness Current/history of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes (angina, MI, stroke, TIA, ischemic bowel disease) History of stroke, transient ischemic attack, or hemiplegic or basilar mraine History of coronary artery disease or coronary artery vasospasm Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders Uncontrolled hypertension DO NOT use IV Within 2 weeks of MAO-A inhibitors Within 24 hours of another 5-HT1 receptor agonist or ergot-type medications Severe hepatic impairment Hypersensitivity Uncontrolled hypertension Use when clear diagnosis of mraine established Equally effective at any stage of mraine, although early use recommended Overuse of acute mraine drugs (eg, ergotamine, triptans, opioids, or combination of these drugs for ≥10 days/month) may lead to exacerbation of headache (medication overuse headache); detoxification may be necessary Binds to melanin, may cause toxicity to melanin-rich tissues on prolonged use Very rare reports of transient and permanent blindness and snificant partial vision loss Serotonin syndrome may occur, particularly during combined use with SSRIs (eg, fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRIs (eg, venlafaxine, duloxetine); discontinue therapy if it occurs Cerebral/subarachnoid hemorrhage and stroke reported with 5-HT1 agonist administration; discontinue if it occurs Snificant elevation of blood pressure, including hypertensive crisis, reported Not for administration to patients with risk factors for coronary artery disease Use caution in patients with history of seizure disorder or lowered seizure threshold May cause depression including dizziness, weakness, or drowsiness (infrequent); caution when operating heavy machinery Coronary artery vasospasm, transient ischemia, ventricular tachycardia/fibrillation, myocardial infarction, cardiac arrest and death reported with use 5HT1 agonists; perform cardiac evaluation in patients with multiple cardiovascular risk factors; evaluate for coronary artery disease in patients at hh risk; discontinue therapy if arrhythmia occurs Use oral formulations with caution in patients with mild-to-moderate hepatic impairment if treatment necessary and advisable; presystemic clearance, when administered orally, is reduced in hepatic impairment and cause an increase in plasma concentrations; dose reduction recommended; when adminsitered parenterally (SC, intranasal), does not undergo first pass metabolism and may not cause increase in plasma concentrations Pregnancy category: C Embryolethality and blood vessel abnormalities observed with PO or IV doses in pregnant rabbits during organogenesis Lactation: Excreted in breast milk at very low levels (NLM TOXNET); minimize infant to potential exposure by avoiding breastfeeding for 8-12 hours after administration Selective 5-HT1B and 5-HT1D receptor agonist in cranial arteries; elicits vasoconstrictive and anti-inflammatory effects; associated with antidromic neuronal transmission and relief of mraine headache Bioavailability: 15% (PO); 97% (SC) Onset: 10 min (SC); 30 min (PO) Duration: 9-24 hr (SC) Peak plasma time: 0.5-3 hr (PO); 5-20 minutes (SC) Peak plasma concentration: 18-51 ng/m L (PO); 55-108 ng/m L (SC, 6 mg dose) The above information is provided for general informational and educational purposes only. The sumatriptan oral tablet Imitrex is used to treat mraine headaches. Sumatriptan may pass into breast milk and may cause side effects in a child who is.
Imitrex - drug review dosage, side effects, action, buy Imitrex Imitrex, which is generiy prescribed as sumatriptan, is commonly used to treat mraines and cluster headaches. It is ineffective in preventing mraines or cluster headaches, however it has been proven effective in treating these painful conditions once the pain has begun. A thorough medical history should be assessed prior to prescribing this medication. Imitrex does pass into the mother's breast milk and may affect a nursing baby. The prescribing physician should avoid prescribing this medication to a pregnant.
Imitrex breast milk:
Rating: 98 / 100
Overall: 97 Rates